VXA-A1.1 + Fluzone®
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Influenza
Conditions
Influenza
Trial Timeline
Aug 31, 2016 → Jan 19, 2018
NCT ID
NCT02918006About VXA-A1.1 + Fluzone®
VXA-A1.1 + Fluzone® is a phase 2 stage product being developed by Vaxart for Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT02918006. Target conditions include Influenza.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02918006 | Phase 2 | Completed |
Competing Products
20 competing products in Influenza